News | Articles | May 8, 2025
Survey Snapshot: Chronic Hand Eczema's Clinical Burden, Treatment Gaps, and Patient Impact Revealed We review survey data revealing diagnostic confusion, treatment gaps, and the emotional, social, and occupational toll of moderate to severe chronic hand eczema.
Newsletter Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Subscribe
October 13th, 2026 In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
October 28th, 2026 A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve early melanoma detection.
October 28th, 2026 Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
October 27th, 2026 Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
October 27th, 2026 Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
October 27th, 2026 ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
October 26th, 2026 LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
October 26th, 2026 ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.